Melanoma/Skin Cancer News

Intralesional immunotherapy shows potential as a treatment for cutaneous malignancies, including nonmelanoma skin cancer, according to a speaker at this year’s ODAC Dermatology, Aesthetic & Surgical Conference.

Evaluating the loss of life expectancy among patients diagnosed with cutaneous melanoma may help establish a lifetime prognosis for patients, according to a study.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving many cancers with high mortality rates and those affecting Black patients underfunded, study results in JCO Oncology Practice showed.

The addition of immunotherapy to perioperative conventional cancer therapy appeared linked to more grade 3 to grade 4 treatment related adverse events, according to findings published in The Lancet Oncology.

Black patients experience higher acral melanoma rates, as well as melanoma-associated mortality rates, compared with white patients, according to a study.

Health care professionals who experienced recent weight loss had a significantly higher risk for a cancer diagnosis during the subsequent 12 months, results of a prospective cohort analysis revealed.

Metabolic changes can be identified in patients with advanced melanoma by imaging tumors within 1 week of beginning immunotherapy, according to a study published in Clinical Cancer Research.

In patients with Fitzpatrick skin types IV through VI, gene expression analysis can help rule out melanoma, according to a poster presented at the Winter Clinical Dermatology Conference.

Substance use disorders are more prevalent among survivors of certain types of cancer, according to study results published in JAMA Oncology.

Non-Hispanic American Indian and Alaskan Native populations exhibited increasing rates of melanoma over the span of two decades, especially in certain parts of the country, according to a study.